Centrally acting antiadrenergic (versus unexposed) updated on 03-11-2025

Tetralogy of Fallot

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S14245
R55971		 Fisher - Centrally acting antiadrenergics (Controls unexposed, disease free), 2017 Tetralogy of Fallot early pregnancy case control unexposed, disease free excluded Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified 1.01 [0.26;2.79]
excluded (control group) 		4/46   -/- - 46
ref
S14247
R55988		 Fisher - Centrally acting antiadrenergics (Controls unexposed, sick), 2017 Tetralogy of Fallot early pregnancy case control unexposed, sick Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified 0.79 [0.20;2.24] 4/46   -/- - 46
ref
Total 1 studies 0.79 [0.24;2.64] 0 46
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Fisher - Centrally acting antiadrenergics (Controls unexposed, sick), 2017Fisher - Centrally acting ant..., 2017 1 0.79[0.20; 2.24]-460%ROB confusion: criticalROB selection: criticalROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate0.22.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0 case control studiescase control studies 0.79[0.24; 2.64]-46 -NAFisher - Centrally acting antiadrenergics (Controls unexposed, sick), 2017 1 Type of controls unexposed, sickunexposed, sick 0.79[0.24; 2.64]-46 -NAFisher - Centrally acting antiadrenergics (Controls unexposed, sick), 2017 1 Tags Adjustment   - No  - No 0.79[0.24; 2.64]-46 -NAFisher - Centrally acting antiadrenergics (Controls unexposed, sick), 2017 1 Indications Antihypertensive   - All hypertensions, any indications ...  - All hypertensions, any indications or not specified 0.79[0.24; 2.64]-46 -NAFisher - Centrally acting antiadrenergics (Controls unexposed, sick), 2017 1 All studiesAll studies 0.79[0.24; 2.64]-46 -NAFisher - Centrally acting antiadrenergics (Controls unexposed, sick), 2017 10.210.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 14245

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.01[0.31; 3.31]-46 -NAFisher - Centrally acting antiadrenergics (Controls unexposed, disease free), 2017 1 unexposed, sick controlsunexposed, sick controls 0.79[0.24; 2.64]-46 -NAFisher - Centrally acting antiadrenergics (Controls unexposed, sick), 2017 10.510.01.0